Trial Profile
A Phase I, Open Label, Parallel Group Study to Evaluate the Effect of Ethnicity on the Pharmacokinetics, Pharmacodynamics and Safety of a DS 1040b IV Infusion Administered to Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs DS 1040 (Primary)
- Indications Pulmonary embolism; Stroke
- Focus Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 01 Sep 2017 Results published in the Clinical Pharmacology in Drug Development : 2017 Annual Meeting of the American College of Clinical Pharmacology.
- 25 Aug 2016 Status changed from recruiting to completed.
- 17 Feb 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.